

MedX Health explains why no one should ever die from skin cancer

InvestorIntel's Tracy Weslosky talks with MedX Health Corp.'s (TSXV: MDX) Executive Chairman & CEO Robert Von Der Porten and Mike Druhan, President of Dermatology Services.

"Nobody should ever die from skin cancer," said Robert. "Unfortunately people still do, and we have technology to solve that problem."

"MedX is in the teledermatology space, so we are sort of a specialized version of telemedicine," Mike said in the interview. "Our ability to go 2mm below the skin and catch a spectrophotometric view of the disorganization under the skin is our hallmark differentiation. Other competing technologies have about 40% rejection rate on the image quality. Our technology does not have a rejection rate because every image is absolutely perfect."

Pointing to their dermatologist-designed questionnaires that form a part of MedX's telemedicine platform, Robert said the advantage is that "dermatologists can very quickly, and time-effectively assess a patient's condition, the surrounding area condition and if it is a mole or lesion, which is potentially cancerous. It is a very powerful platform that can be deployed anywhere."

To access the complete interview, [click here](#)

Disclaimer: MedX Health Corp. is an advertorial member of InvestorIntel Corp.

James Howard-Tripp on applying StageZero's cancer diagnostics expertise to COVID-19 testing

InvestorIntel's Tracy Weslosky talks with James Howard-Tripp, Chairman and CEO of StageZero Life Sciences Ltd. (TSX: SZLS), about StageZero's early detection of cancer diagnostics and its new testing technology for COVID-19. Tracy observed, "You have one of the highest volume stock. You recently had a buy recommendation from Clarus Securities. What do you attribute all this recent attention to?" she asked.

"Fifteen years of work," James replied.

"We are a cancer diagnostic company. So, when you deal with cancer everything needs to be absolutely precise," James added. "When you move into another line, which is testing for COVID-19, you have to bring the exact same rigor to it. Everything that we do is to ensure that it is as precise as possible." StageZero's Aristotle testing platform can identify ten different types of cancer from a single blood test. "We believe that it will be in the market by year end. We are now completing the last of the validation," James said.

To watch the complete interview, [click here](#)

Disclaimer: StageZero Life Sciences Ltd. is an advertorial member of InvestorIntel Corp.

David Morgan on why the gold and silver ride is not over yet

InvestorIntel's Tracy Weslosky asks David Morgan, Founder & Owner of The Morgan Report, if it is too late to invest in the gold and silver market. "From my work and many others we are in the last leg of this major move." David said. "The greatest price appreciation takes place in the last leg, but the last leg is usually short in duration. 90% of the move comes in the last 10% of the time."

"We are in a monetary conundrum," David told Tracy. "We are printing our way out of a mess that can't be printed out of. So, the metals are going to react to that in a very significant way, probably in a very short duration. Juniors are the last to participate in any cycle," David added. "I think there is so much pressure in the precious metals right now, juniors may participate a little earlier than they normally do."

Last month InvestorIntel announced its partnership with **InvestorChannel.com**, a data-driven fintech company that is focused on using the latest in artificial intelligence (AI) and other analytics technologies to develop a platform that produces timely insights into companies and industries listed on the capital markets. InvestorChannel publishes a daily Silver Stocks Watchlist Update video which includes the Top 5 Performers of the Day and a performance review of the companies InvestorChannel is following in the sector, carefully selected by silver expert David Morgan of The Morgan Report.

To watch the complete interview, [click here](#)

Euro Sun Mining's Rovina Valley Gold Project getting the attention it deserves

InvestorIntel's Peter Clausi talks with Scott Moore, President and CEO of Euro Sun Mining Inc. (TSX: ESM) about Euro Sun's Rovina Valley Gold Project. "We are probably one of the cleanest projects out there. We don't use cyanide. We don't use wet tailings," Scott said. "Porphyry projects usually have big CapEx. We don't have a big CapEx," he added, owing to cheap power, skilled labour force and great infrastructure. "It is big. We can move earth inexpensively and we can make a lot of money particularly with the simple processing that we have."

Scott also provided an update on Euro Sun's recently closed C\$22.3 million bought deal financing. "We had \$17 million of institutional demand in the financing," he said. "The institutional demand was international, from United States, Hong Kong, Paris, and London with three of the largest funds that are out there – Ruffer, Franklin Templeton and ASA Gold taking significant positions." Commenting on what's coming up for Euro Sun, Scott noted that "the stock has gone from 15 cents in March to 60 cents now," with "some significant catalysts coming up in the next 6 to 12 months."

To watch the complete interview, [click here](#)

Disclaimer: Euro Sun Mining Inc. is an advertorial member of InvestorIntel Corp.

The Rare Earths War

Technology Metals Show host Tracy Weslosky moderates a timely discussion on how China poses a serious threat to the rare earths supply chain security of the United States, talking to international rare earths expert Jack Lifton and the Editor of "The Rare Metals War" Guillaume Pitron. Guillaume observed that Donald Trump as the President has been tackling the rare earths supply chain issue like no one ever done in this role. He added, "If he is re-elected, I believe, that is going to impact in a good way the US production of rare earth minerals and rare earth metals."

Jack agreed with Guillaume and added, "Trump is the first president to refocus on globalization, and he is trying to de-globalize critical materials for the security of the United States." Highlighting the seriousness of the rare earths supply chain problem, Jack said that Shin-Etsu and Hitachi, two large Japanese companies that supply rare earth magnets to the US military, have most of their production in China.

Jack also revealed that China recently announced that they would cut off Northrop Grumman, an American defense technology company, from all Chinese rare earth materials. "What Americans don't seem to be paying attention to," Jack continued, "is Grumman is the producer of the F-35 fighter plane, the greatest air superiority weapon in history. Grumman needs those rare earths to build those planes. This is going to bring real pressure on the defense department."

To access the complete interview subscribe to the **Technology Metals Show** and get exclusive access to members-only content through this exclusive site. Or [Log-In Here](#) for the latest conversations, debates, updates and interviews with the

leaders, thought leaders and investors focused on issues relating to sustainability in the critical materials sector.

For more information on the **Technology Metals Show** email us at info@technologymetals.com or reach us direct at +1 (416) 546-9233

Don Bubar on Avalon's 20 years in rare earths and their diversified asset base of critical materials

"We have been in rare earths business for over 20 years now," Don Bubar, President, CEO and Director of Avalon Advanced Materials Inc. (TSX: AVL | OTCQB: AVLNF), tells InvestorIntel's Tracy Weslosky in an interview. "And we are very well known among investors in the US for our lead role in the rare earths bubble 10 years ago. Whenever there is new development and news headline related to the risk on security of supply, then you will see speculative trading activity in Avalon."

"Our strategy has been to have a diversified asset base," Bubar continued. "That gives us exposure to broad range of these new emerging critical materials. We are basically positioned to react to when there is a new demand in the marketplace."

Bubar went on to say that Avalon is working with a partner on its Nechalacho rare earth elements property and has maintained its main resource for any future upside. "We continue to look

at other possibilities to create new rare earths supplies, by looking at how we can use new technology to recover rare earths from non-traditional sources such as historic mine wastes,” he said.

Bubar also commented on Avalon’s Separation Rapids Lithium Project: “Our focus now is on taking advantage of the opportunity in lithium markets. We are permitted now to recover a bulk sample to finalize our process flowsheet, do a pilot plant run and produce some product samples for customers who have expressed interest in the product in the glass industry as well as start to revisit serving the battery materials market going forward.”

To access the complete interview, [click here](#).

Disclaimer: Avalon Advanced Materials Inc. is an advertorial member of InvestorIntel Corp.

Predictmedix’s Dr. Rahul Kushwah on using AI to solve real world problems

Using artificial intelligence to mass screen for COVID-19

“It’s about the different verticals that we are addressing with Predictmedix,” says Dr. Rahul Kushwah, Co-Founder and COO of Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF). “We are an artificial intelligence company and we are solving real-world problems.”

In an interview with InvestorIntel’s Tracy Weslosky, Dr. Kushwah explains three of their vertical markets: “COVID-19

pandemic, we are all in the midst of it and we have a technology which is to mass screen for COVID-19. Similarly, impairment is a big issue when it comes to workplace and law enforcement and we have a solution for that. And the third vertical is mental illnesses. \$300 billion spent in the US last year and there is so much subjectivity that goes into diagnosis and we are developing a solution to diagnose mental illnesses.”

“We have developed modules which look like metal detectors,” Dr. Kushwah continued. “You walk through these modules and on the other end you have a green or red light. If someone is identified to be positive for COVID-19 symptoms a red light goes off – if not then you get a green light.” He continued, “it is a tool that you can use for mass screening in airports, transit hubs, malls, office building, government buildings, or anywhere you can imagine where you have big flow of people.” Dr. Kushwah also discusses the pitfalls of current telehealth and telemedicine platforms, and Predictmedix’s innovative solutions.

To access the complete interview, [click here](#)

Disclaimer: Predictmedix Inc. is an advertorial member of InvestorIntel Corp.